Pharmaceutical Industry news, analysis and insights
Eli Lilly has announced that tirzepatide (10mg and 15mg) achieved significant and superior weight loss compared to a placebo over 72 weeks of treatment. This data follows results from the surmount-2 trial, which met all co-primary and secondary endpoints.
AstraZeneca and Ionis have announced positive results from their phase 3 neuro-ttransform trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (attrv-pn), showing that the companies’ drug eplontersen met all primary and secondary endpoints at 66 weeks compared to an external placebo group.
AbbVie has shared positive results from its phase 3 elevate study, which assessed atogepant for the preventative treatment of episodic migraines in patients who have previously had two to four unsuccessful classes of oral preventive medications.
Eli Lilly has announced positive results from the trailblazer-alz 2 phase 3 trial assessing donanemab’s ability to slow cognitive and functional decline in people with early symptomatic Alzheimer’s disease.
Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, cross-over clinical study of endothelial dysfunction.